Top Markets
#1 0G 0G +41.72%
#2 Merlin's Seal BTC Merlin's Seal BTC +37.19%
#3 Useless Coin Useless Coin +36.56%
#4 Arbitrum Arbitrum +30.16%
#5 SAFEcoin SAFEcoin +29.17%
#6 StonkBroker StonkBroker +27.88%
#7 Pons Pons +22.11%
#8 Notcoin Notcoin +21.42%
#9 Zora Zora +18.97%
#10 Full Moon Full Moon +18.20%
Coin of the day
0G 0G
Settings
Language
ENGLISH
Currency
USD
Theme
EirGenix Inc. EirGenix Inc.

EirGenix Inc.

6589
Rank in Stocks #14111
EirGenix Inc., founded in 2012 and based in New Taipei City, Taiwan, functions... EirGenix Inc., founded in 2012 and based in New Taipei City, Taiwan, functions as a contract development and manufacturing organization (CDMO) with operations spanning both domestic and international markets. The company offers a comprehensive range of services, encompassing cell line creation, process optimization, analytical testing and quality control, and current Good Manufacturing Practice (cGMP) compliant production utilizing both mammalian and microbial expression systems. They also specialize in services related to antibody-drug conjugates (ADCs). Beyond its service offerings, EirGenix is actively engaged in developing several therapeutic candidates. This pipeline includes EG12014/EGI014, a Trastuzumab biosimilar intended for cancer therapy, which has reached the biologics license application (BLA) submission stage. Other oncology-focused developments are EG1206A, a Pertuzumab biosimilar currently in Phase I clinical trials; EG13074, in preclinical development; and TSY0110(EG12043), an antibody-drug conjugate also in preclinical stages. Additionally, the company is advancing EG12021, a Bevacizumab biosimilar for cancer treatment, and EG62054, another biosimilar, both in preclinical development. In addition to its core activities, EirGenix manufactures and distributes a rapid antigen test for COVID-19, as well as the CRM197 carrier protein under the designation EG74032.
Share Price
$1.46
Last synced: 2026-07-28
Market Cap
$435.25M
Change (1 day)
-2.34%
Change (1 year)
-26.63%
Country
TW
Trade EirGenix Inc. (6589)

Category

Healthcare
Operating Margin for EirGenix Inc. (6589)
Operating Margin as of 2026 TTM: 0.00%
According to EirGenix Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for EirGenix Inc. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.